The DOI matches its Crossref record.
A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses
Abstract
BACKGROUND: Actinic keratoses (AKs) are precancerous epidermal lesions found most frequently on areas of the skin exposed to the sun. Several case studies published recently have indicated that 5% imiquimod cream, currently licensed for the treatment of genital warts, may be an effective treatment for AK. OBJECTIVE: To assess the efficacy and safety of imiquimod for the treatment of AK. DESIGN: Patients in this randomized, double-blind, vehicle-controlled study applied 5% imiquimod cream or vehicle to AK lesions 3 times per week for a maximum of 12 weeks or until lesions had resolved. In the event of an adverse reaction, application of imiquimod was reduced to 1 or 2 times per week. Rest periods were also allowed if necessary. SETTING: A specialized outpatient dermatology clinic within a state-funded hospital in Germany. PATIENTS: The study population was aged 45 to 85 years. Of 52 patients screened, 36 men and women with AK confirmed by histological diagnosis were enrolled. Patients were excluded from the study if they did not have a histological diagnosis for AK, if they were older than 85 years, or if they did not comply with the protocol. All patients had responded to a notice asking for volunteers. MAIN OUTCOME MEASURES: The number and appearance of lesions were evaluated before, during, and after treatment. All adverse effects were recorded. RESULTS: Lesions treated with 5% imiquimod cream were clinically cleared in 21 (84%) of 25 patients and partially cleared in 2 (8%). Clearance was histologically confirmed 2 weeks after the last application of imiquimod in all patients clinically diagnosed as lesion free. Only 10% of patients treated with imiquimod were clinically diagnosed with recurrence 1 year after treatment. No reduction in the size or number of AK lesions was observed in vehicle-treated patients. Adverse effects reported by patients treated with imiquimod included erythema, edema, induration, vesicles, erosion, ulceration, excoriation, and scabbing. However, imiquimod was well tolerated since all patients completed the 12-week treatment. Only a few, mild adverse reactions to the vehicle cream were reported. CONCLUSION: Application of 5% imiquimod cream for 12 weeks is an effective and well-tolerated treatment for AK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TLR7 and TLR8 as targets in cancer therapy
Schön, M. P., & Schön, M. (2008) · Oncogene · doi:10.1038/sj.onc.1210913 · Cited by 296
Guidelines for the management of actinic keratoses
de Berker, D., McGregor, J. M., Hughes, B. R., & on behalf of the British Association of Dermatologists Therapy Guidelines and Audit Subcommittee (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07692.x · Cited by 296
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J., Lee, J. H., & Fox, T. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.010 · Cited by 293
Touma, D., Yaar, M., Whitehead, S., Konnikov, N., & Gilchrest, B. A. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.1.33 · Cited by 263
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Engel, A. L., Holt, G. E., & Lu, H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.5 · Cited by 205
Metadata
- Authors
- Stockfleth, E.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2002-11-01
- Volume
- 138
- Issue
- 11
- Pages
- 1498
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2064019766
- Cited by
- 205
- References
- 0
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses. https://app.cochat.ai/papers/10.1001/archderm.138.11.1498
- The paper
- Stockfleth, E. (2002). A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses. Archives of Dermatology. https://doi.org/10.1001/archderm.138.11.1498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.